Aberrant MEK5 signalling promotes clear cell renal cell carcinoma development via mTOR activation

Battaglia M et al (2006) Rapamycin promotes expansion of functional CD4+ CD25+ FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 177(12):8338–8347

Article  CAS  PubMed  Google Scholar 

Cargnello M et al (2011) Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 75(1):50–83

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cristea S et al (2020) The MEK5–ERK5 kinase axis controls lipid metabolism in small-cell lung cancer. Can Res 80(6):1293–1303

Article  CAS  Google Scholar 

El Dib R, Touma NJ, Kapoor A (2012) Cryoablation vs. radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies. BJU Int 110(4):510–516

Article  PubMed  Google Scholar 

Goyal R et al (2013) Differential diagnosis of renal tumors with clear cytoplasm: clinical relevance of renal tumor subclassification in the era of targeted therapies and personalized medicine. Arch Pathol Lab Med 137(4):467–480

Article  CAS  PubMed  Google Scholar 

Guo H et al (2015) The PI3K/AKT pathway and renal cell carcinoma. J Genet Genomics 42(7):343–353

Article  PubMed  PubMed Central  Google Scholar 

Hayashi M et al (2005) Big mitogen-activated protein kinase 1/extracellular signal-regulated kinase 5 signaling pathway is essential for tumor-associated angiogenesis. Can Res 65(17):7699–7706

Article  CAS  Google Scholar 

Hirayama Y et al (2016) Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma. Cancer Sci 107(12):1736–1744

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang S (2020) mTOR Signaling in metabolism and cancer. Cells 9(10):2278

Article  CAS  PubMed Central  Google Scholar 

Huijts CM et al (2019) The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial. Cancer Immunol Immunother 68(3):503–515

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jacinto E, Werlen G (2015) mTOR: The mTOR complexes in T cell development and immunity encyclopedia of inflammatory diseases. Springer, Berlin, Germany

Google Scholar 

Khan MA et al (2019) PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discov Today 24(11):2181–2191

Article  CAS  PubMed  Google Scholar 

Liu GY, Sabatini DM (2020) mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol 21(4):183–203

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu F, Zhang H, Song H (2017) Upregulation of MEK5 by Stat3 promotes breast cancer cell invasion and metastasis. Oncol Rep 37(1):83–90

Article  CAS  PubMed  Google Scholar 

Ljungberg B et al (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924

Article  PubMed  Google Scholar 

Magaway C, Kim E, Jacinto E (2019) Targeting mTOR and metabolism in cancer: lessons and innovations. Cells 8(12):1584

Article  CAS  PubMed Central  Google Scholar 

Makarević J et al (2018) HDAC inhibition counteracts metastatic re-activation of prostate cancer cells induced by chronic mTOR suppression. Cells 7(9):129

Article  PubMed Central  Google Scholar 

Mehta P et al (2003) MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 22(9):1381–1389

Article  CAS  PubMed  Google Scholar 

Meskawi M et al (2012) A review of integrated staging systems for renal cell carcinoma. Eur Urol 62(2):303–314

Article  PubMed  Google Scholar 

Miranda M et al (2015) MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments. Oncoscience 2(2):99

Article  PubMed  PubMed Central  Google Scholar 

Montero JC et al (2009) Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS ONE 4(5):e5565

Article  PubMed  PubMed Central  Google Scholar 

Mossmann D, Park S, Hall MN (2018) mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer 18(12):744–757

Article  CAS  PubMed  Google Scholar 

Motzer RJ et al (2014) Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 370(18):1769–1770

Article  CAS  PubMed  Google Scholar 

Pereira DM et al (2016) MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism. Oncotarget 7(23):34322

Article  PubMed  PubMed Central  Google Scholar 

Perez-Madrigal D et al (2012) The extracellular-regulated protein kinase 5 (ERK5) promotes cell proliferation through the down-regulation of inhibitors of cyclin dependent protein kinases (CDKs). Cell Signal 24(12):2360–2368

Article  CAS  PubMed  Google Scholar 

Pierorazio PM et al (2015) Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol 68(3):408–415

Article  PubMed  Google Scholar 

Ramsay A et al (2011) ERK5 signalling in prostate cancer promotes an invasive phenotype. Br J Cancer 104(4):664–672

Article  CAS  PubMed  PubMed Central  Google Scholar 

Razumovskaya E, Sun J, Rönnstrand L (2011) Inhibition of MEK5 by BIX02188 induces apoptosis in cells expressing the oncogenic mutant FLT3-ITD. Biochem Biophys Res Commun 412(2):307–312

Article  CAS  PubMed  Google Scholar 

Rini BI, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373(9669):1119–1132

Article  CAS  PubMed  Google Scholar 

Rini BI et al (2016) Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer 4(1):1–15

Article  PubMed Central  Google Scholar 

Simioni C et al (2019) Targeting mTOR in acute lymphoblastic leukemia. Cells 8(2):190

Article  CAS  PubMed Central  Google Scholar 

Simões A et al (2015) Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κ B activation. Cell Death Dis 6(4):e1718–e1718

Article  PubMed  PubMed Central  Google Scholar 

Sohn SJ et al (2005) Transcriptional regulation of tissue-specific genes by the ERK5 mitogen-activated protein kinase. Mol Cell Biol 25(19):8553–8566

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tan FH et al (2019) mTOR signalling in head and neck cancer: heads up. Cells 8(4):333

Article  CAS  PubMed Central  Google Scholar 

Wang X, Tournier C (2006) Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal 18(6):753–760

Article  CAS  PubMed  Google Scholar 

Wolff I et al (2016) Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database. Eur J Surg Oncol (EJSO) 42(5):744–750

Article  CAS  Google Scholar 

Wright TD et al (2020) Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer. J Cell Biochem 121(2):1156–1168

Article  CAS  PubMed  Google Scholar 

Zen K et al (2009) ERK5 is a target for gene amplification at 17p11 and promotes cell growth in hepatocellular carcinoma by regulating mitotic entry. Genes Chromosom Cancer 48(2):109–120

Article  CAS  PubMed  Google Scholar 

留言 (0)

沒有登入
gif